QPPV.COM KNOWLEDGE ASSESSMENT

Benralizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Benralizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which case feature would be most important when evaluating a suspected delayed hypersensitivity reaction after benralizumab?

Only the patient's pre-treatment eosinophil count Dose number, latency, clinical features, treatment, resolution and any re-exposure Only whether the patient had asthma before treatment The patient's indication without any information about the injection

Question 2 of 10 A patient develops fatigue, hypotension and worsening respiratory symptoms while reducing long-term oral corticosteroids after starting benralizumab. What should the case assessment prioritise?

Attributing all symptoms directly to benralizumab without further review Reconstructing the steroid taper and evaluating adrenal insufficiency, disease activity and other competing explanations Interpreting the symptoms as evidence that eosinophil depletion is absent Assessing only the injection device

Question 3 of 10 What is the most informative way to use anti-drug antibody results in a benralizumab case?

Store the result separately without linking it to clinical events Use the result in relation to eosinophil recovery, loss of response or a hypersensitivity phenotype Assume that any detectable antibody proves clinical failure Use anti-drug antibody status instead of documenting dosing history

Question 4 of 10 Which sequence most accurately represents the cellular mechanism of benralizumab-mediated eosinophil depletion?

IL-5 degradation, followed by eosinophil proliferation and tissue retention IL-5Rα binding, effector-cell Fc engagement, cytolytic synapse formation and eosinophil apoptosis Complement inhibition, followed by increased eosinophil maturation in bone marrow Corticosteroid receptor activation, followed by nonspecific leukocyte suppression

Question 5 of 10 Which description best captures the principal pharmacological distinction between benralizumab and an antibody that neutralises soluble IL-5?

Benralizumab blocks IL-5Rα and uses its engineered Fc region to promote depletion of IL-5Rα-expressing cells Benralizumab binds circulating IL-5 and prevents its synthesis in the bone marrow Benralizumab selectively inhibits corticosteroid receptors in eosinophils Benralizumab primarily neutralises IgE and prevents mast-cell activation

Question 6 of 10 Which statement best expresses the central benefit-risk principle for benralizumab across its authorised disease settings?

The same blood eosinophil reduction represents the same clinical benefit in every indication Clinical benefit depends on how eosinophil-driven pathology manifests in the specific disease, so organ and disease outcomes must accompany biomarker assessment Any reduction in eosinophils is evidence that risk is outweighed by benefit Benefit-risk assessment should focus exclusively on hypersensitivity events

Question 7 of 10 Which information is most useful when assessing a possible lack of efficacy in severe eosinophilic asthma?

Only the date of the most recent injection Baseline exacerbation history, treatment duration, adherence, eosinophils, corticosteroid use and possible triggers Only whether the patient experienced one symptom after initiation The batch number without any disease or treatment information

Question 8 of 10 What is the most appropriate handling of a patient with a known helminth infection who is being considered for benralizumab?

Ignore the infection because eosinophil depletion treats all parasitic disease Manage the infection appropriately and evaluate persistent infection during treatment Use the eosinophil count alone to determine whether treatment is safe Assume that any subsequent infection is necessarily caused by benralizumab

Question 9 of 10 A patient develops worsening wheeze several hours after an injection. Which approach best reflects the article's pharmacovigilance guidance?

Classify the event automatically as an allergic reaction Exclude any relationship because the reaction was not immediate Assess the event differentially, considering hypersensitivity alongside asthma activity and other explanations Record only the eosinophil count and omit the clinical chronology

Question 10 of 10 What is the main functional consequence of afucosylation in benralizumab's Fc region?

Reduced binding to IL-5Rα so that receptor signalling is only partially inhibited Increased affinity for FcγRIIIa/CD16a on effector cells, strengthening antibody-dependent cellular cytotoxicity Increased renal clearance of the antibody and shortened systemic exposure Prevention of all immune-cell binding to the antibody Fc region

Benralizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings